The US is introducing a new method to combat sexually transmitted infections (STIs) using an old antibiotic.
DoxyPEP, or doxycycline when used after unprotected sex, is proving to be a powerful tool against chlamydia, gonorrhea, and syphilis. But there’s a dilemma.
The Center for Disease Control and Prevention (CDC) is working on guidelines for doctors to use this method.
They’re juggling the need to combat increasing STI cases with concerns about making some STIs resistant to antibiotics.
Jonathan Mermin, a top official at the CDC, highlights the urgency for new approaches in public health. The upcoming guidelines from the CDC will be specific.
They will likely advise the drug’s use for high-risk groups like gay men and transgender women with histories of past infections.
Why the Concern?
STIs have been on the rise in the US. In 2021, 2.5 million cases of three bacterial STIs were reported. Several factors contribute to this surge.
With HIV prevention pills (PrEP) becoming common, condom use has decreased. Moreover, regular screenings for those on PrEP probably led to the discovery of more STI cases.
It’s also a numbers game. More infected people mean a higher risk of the infections spreading.
In research, DoxyPEP was found to be effective. Annie Luetkemeyer, a researcher, noted that the pill reduced STIs by about two-thirds every three months in their trials. The results were especially good against chlamydia and syphilis.
Antibiotic Resistance: A Real Fear?
There are concerns. Using DoxyPEP widely might make STIs like gonorrhea resistant to doxycycline. But early studies give a mixed picture.
Some research suggests that the pill might be less effective against already resistant strains rather than causing new resistance. On the upside, if DoxyPEP reduces STI cases, fewer people will need treatment with other antibiotics.
Researchers believe that DoxyPEP can be part of a larger strategy in treating STIs, alongside other measures like vaccines.
Public Response and Future Steps
For many, like Malik from Washington, DoxyPEP is seen as a backup after unprotected sex.
Malik’s personal experience underscores a cultural shift – fewer people want to use condoms. Stephen Abbott, a doctor, thinks that the role of condoms in prevention might be reducing.
People globally have heard about DoxyPEP. Some are even sourcing it outside official channels. A man from London shared that he had to rely on black market sources and friends for the drug.
Researchers like Luetkemeyer remain hopeful. While DoxyPEP isn’t the complete solution to the rising STI problem, it’s a step in the right direction.
The fight against STIs might soon have a combination of old drugs, new guidelines, and upcoming vaccines.
If you care about medicine, please read studies about drug that could inhibit COVID-19 virus, and drug for inflammation may stop spread of cancer.
For more information about medicine, please see recent studies about which drug can harm your liver most, and results showing this drug can give your immune system a double boost against cancer.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
